Thomas Freeman: Yes. Hey, I’m Thomas here. Yes, I think that’s exactly right. So, particularly coming out of the third quarter with the favorable utilization that we’ve been able to achieve year-to-date, we also invested a few million dollars and plan to invest a bit more ahead in the Q4 regarding some of our clinical engagement in annual wellness activities, which is really about setting us up for a successful 2024 and beyond. To your point, we also then added that we did raise our guidance for the full-year by 4,000 roughly members at the midpoint, which, as our year one members typically do have higher MBRs than our loyal or returning members. So, that’s the second part of the driver. But I would think about it as favorable outperformance and utilization, essentially funding a lot of these investments that we’re making to set us up for a successful 2024 and then the incremental growth on top of that.
Adam Ron: It makes sense. And then, I guess following up on the discussion from last quarter, we’re like national payers and MA had problems with utilization and you weren’t really seeing it. But now that you have more claims data from like May and April and the time period from when payers are really worried about utilization, is there anything that you are seeing that’s similar to that commentary or you’re still really having a different experience from all the other public companies and if so, is it just like geography that would explain the difference or what else would you point to?
Thomas Freeman: Yes, so from an outpatient standpoint similar to our comments last quarter we have not seen a considerable increase in 2023 relative to our 2022 experience. So, I think on a year-over-year basis our overall outpatient claims PMPM are up in the low single digits, again, within the realm expectations had into this year. I think our theory as to why that is twofold. So, I think, first of all, we saw a pretty considerable increase in our applications been in ’22 relevant to 2021. And so, I think to a certain extent, for us based on the markets wherein or other factors, I think we saw some of that return maybe earlier than others. And that was captured as part of our run rate in ’22 heading in 2023. I think additionally, while a lot of our focus with care anywhere is on those chronic complex members, who we have the opportunity to really improve things like unnecessary or affordable hospital admission improve their readmission rates and things of that nature.
I do think there’s obviously some benefit with our broader clinical model and provider engagement efforts that helps on the outpatient side as well. It seems to be less of the material driver where we generate the savings, but I think that’s a tailwind for us relative as many of our competitors.
Adam Ron: Awesome, thanks.
Operator: Thank you. And I show our last question comes from the line of John Ransom from Raymond Jain please go ahead.
John Ransom: Hey, there. Thanks for the follow up. There’s been some industry trade chatter that your hospitals have dropping MA plans and it’s getting harder to assemble that works. How is your go to network strategy to change or not change and why of some of that or do you think that’s over one?
John Kao: Yes, hey, John. It’s John. I’ll take that one. Yes. No, there’s been a lot of public scrutiny around this topic where you’ve had health systems that have entered into global capital arrangements with different pairs exit the business, and they’re just not taking a global capital anymore. And in the conversation that I’ve had with many of the help system’s CEOs, they aren’t concerned about the headwinds associates with Stars funding and V28 funding. And so, when you’re taking global cap, and I’ve said this from the get go, you got essentially two insurance companies within one supply chain, and there’s not enough money to go around right now. And so, that’s why a lot of this sensors are getting out of it. And the other problem with the health systems have right now is access in capacity problems.